Overview

Long-term Safety Study for GSK573719 in Japanese

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the safety and tolerability of GSK573719 Inhalation Powder 125 mcg once-daily over 52 weeks in Japanese subjects with COPD.

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline